HomeALCLS • EPA
add
Cellectis SA
Previous close
€4.29
Day range
€4.26 - €4.67
Year range
€1.01 - €4.84
Market cap
322.14M EUR
Avg Volume
480.17K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 37.16M | 105.89% |
Operating expense | 29.12M | 1.05% |
Net income | 589.00K | 102.55% |
Net profit margin | 1.58 | 101.24% |
Earnings per share | 0.02 | 109.09% |
EBITDA | 11.16M | 239.56% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 52.24M | -67.16% |
Total assets | 343.04M | -13.35% |
Total liabilities | 242.57M | -8.96% |
Total equity | 100.48M | — |
Shares outstanding | 72.33M | — |
Price to book | 3.08 | — |
Return on assets | 5.77% | — |
Return on capital | 10.65% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 589.00K | 102.55% |
Cash from operations | -1.57M | 73.05% |
Cash from investing | -3.44M | -115.41% |
Cash from financing | -4.26M | -1.00% |
Net change in cash | -7.57M | -175.32% |
Free cash flow | -9.76M | -141.30% |
About
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Founded
1999
Website
Employees
219
